| Fused deposition modeling (FDM) 3D printed tablets for intragastric floating delivery of domperidone X Chai, H Chai, X Wang, J Yang, J Li, Y Zhao, W Cai, T Tao, X Xiang Scientific reports 7 (1), 2829, 2017 | 295 | 2017 |
| Resveratrol for cancer therapy: Challenges and future perspectives B Ren, MXY Kwah, C Liu, Z Ma, MK Shanmugam, L Ding, X Xiang, ... Cancer letters 515, 63-72, 2021 | 192 | 2021 |
| Influence of ABCB1 and ABCG2 polymorphisms on doxorubicin disposition in Asian breast cancer patients S Lal, ZW Wong, E Sandanaraj, X Xiang, PCS Ang, EJD Lee, B Chowbay Cancer science 99 (4), 816-823, 2008 | 139 | 2008 |
| High performance liquid chromatography–tandem mass spectrometry for the determination of bile acid concentrations in human plasma X Xiang, Y Han, M Neuvonen, J Laitila, PJ Neuvonen, M Niemi Journal of Chromatography B 878 (1), 51-60, 2010 | 117 | 2010 |
| Pharmacogenetics of SLCO1B1 gene and the impact of* 1b and* 15 haplotypes on irinotecan disposition in Asian cancer patients X Xiang, SR Jada, HH Li, L Fan, L San Tham, CI Wong, SC Lee, R Lim, ... Pharmacogenetics and genomics 16 (9), 683-691, 2006 | 112 | 2006 |
| Targeting hypoxia-inducible factor-1, for cancer treatment: Recent advances in developing small-molecule inhibitors from natural compounds Z Ma, X Xiang, S Li, P Xie, Q Gong, BC Goh, L Wang Seminars in cancer biology 80, 379-390, 2022 | 102 | 2022 |
| Novel SLC22A16 polymorphisms and influence on doxorubicin pharmacokinetics in Asian breast cancer patients S Lal, ZW Wong, SR Jada, X Xiang, X Chen Shu, PCS Ang, WD Figg, ... Future Medicine Ltd 8 (6), 567-575, 2007 | 98 | 2007 |
| A unique CDK4/6 inhibitor: current and future therapeutic strategies of abemaciclib QY Chong, ZH Kok, X Xiang, ALA Wong, WP Yong, G Sethi, PE Lobie, ... Pharmacological Research 156, 104686, 2020 | 75 | 2020 |
| Effect of SLCO1B1 polymorphism on the plasma concentrations of bile acids and bile acid synthesis marker in humans X Xiang, Y Han, M Neuvonen, MK Pasanen, A Kalliokoski, JT Backman, ... Pharmacogenetics and genomics 19 (6), 447-457, 2009 | 69 | 2009 |
| Targeting hypoxia-inducible factor-1-mediated metastasis for cancer therapy Z Ma, LZ Wang, JT Cheng, WST Lam, X Ma, X Xiang, ALA Wong, BC Goh, ... Antioxidants & redox signaling 34 (18), 1484-1497, 2021 | 63 | 2021 |
| The double-edged sword of H19 lncRNA: Insights into cancer therapy YWS Lim, X Xiang, M Garg, MTN Le, ALA Wong, L Wang, BC Goh Cancer Letters 500, 253-262, 2021 | 58 | 2021 |
| Celastrol in cancer therapy: Recent developments, challenges and prospects HY Lim, PS Ong, L Wang, A Goel, L Ding, ALA Wong, PC Ho, G Sethi, ... Cancer Letters 521, 252-267, 2021 | 57 | 2021 |
| Prediction of oral hepatotoxic dose of natural products derived from traditional Chinese medicines based on SVM classifier and PBPK modeling S Li, Y Yu, X Bian, L Yao, M Li, YR Lou, J Yuan, H Lin, L Liu, B Han, ... Archives of Toxicology 95, 1683-1701, 2021 | 55 | 2021 |
| The potential role of exosomal circRNAs in the tumor microenvironment: insights into cancer diagnosis and therapy J Li, G Zhang, CG Liu, X Xiang, MTN Le, G Sethi, L Wang, BC Goh, Z Ma Theranostics 12 (1), 87, 2022 | 53 | 2022 |
| Pharmacogenetics of target genes across the warfarin pharmacological pathway S Lal, SR Jada, X Xiang, WT Lim, EJD Lee, B Chowbay Clinical pharmacokinetics 45, 1189-1200, 2006 | 49 | 2006 |
| A review on liquid chromatography-tandem mass spectrometry methods for rapid quantification of oncology drugs ALA Wong, X Xiang, PS Ong, EQY Mitchell, N Syn, I Wee, AP Kumar, ... Pharmaceutics 10 (4), 221, 2018 | 47 | 2018 |
| Dose selection of chloroquine phosphate for treatment of COVID-19 based on a physiologically based pharmacokinetic model C Cui, M Zhang, X Yao, S Tu, Z Hou, VSJ En, X Xiang, J Lin, T Cai, ... Acta Pharmaceutica Sinica B 10 (7), 1216-1227, 2020 | 45 | 2020 |
| Extracellular vesicles, the cornerstone of next-generation cancer diagnosis? J Weng, X Xiang, L Ding, ALA Wong, Q Zeng, G Sethi, L Wang, SC Lee, ... Seminars in cancer biology 74, 105-120, 2021 | 44 | 2021 |
| Prediction of drug–drug interaction between tacrolimus and principal ingredients of Wuzhi capsule in Chinese healthy volunteers using physiologically‐based pharmacokinetic … H Zhang, F Bu, L Li, Z Jiao, G Ma, W Cai, X Zhuang, HS Lin, JG Shin, ... Basic & Clinical Pharmacology & Toxicology 122 (3), 331-340, 2018 | 42 | 2018 |
| Gender, but not CYP7A1 or SLCO1B1 Polymorphism, Affects the Fasting Plasma Concentrations of Bile Acids in Human Beings X Xiang, JT Backman, PJ Neuvonen, M Niemi Basic & clinical pharmacology & toxicology 110 (3), 245-252, 2012 | 42 | 2012 |
